InvestorsHub Logo
Followers 114
Posts 11230
Boards Moderated 0
Alias Born 11/02/2009

Re: None

Friday, 03/27/2020 1:44:46 AM

Friday, March 27, 2020 1:44:46 AM

Post# of 1612
Everyone ready for tomorrow morning’s conference call? I love that the CEO moved earning up to an earlier date. I also love the fact “AdCOVID” is now listed as one of the companiy’s products in the “About Altimmune” section at the bottom of the PR.

https://apnews.com/Globe%20Newswire/bdb4b6c6dcf0a93c177acc37a3ec84a4

Altimmune to Announce Year End 2019 Financial Results on March 27
Altimmune, Inc.
March 25, 2020
GAITHERSBURG, Md., March 25, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the year ended December 31, 2019 and host a conference call on Friday, March 27, 2020.

Conference Call Details
Date: Friday, March 27
Time: 8:30 am Eastern Time
Domestic: 877-423-9813
International: 201-689-8573
Conference ID: 13701071
Webcast: http://public.viavid.com/index.php?id=138792

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver disease, immune modulating therapies and vaccines. Our diverse pipeline of product candidates includes next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX™, NasoShield™ and AdCOVID). For more information on Altimmune, please visit www.altimmune.com.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ALT News